Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Convertible Debt (2023)

Serina Therapeutics' Convertible Debt history spans 1 years, with the latest figure at $3.0 million for Q4 2023.

  • For Q4 2023, Convertible Debt changed N/A year-over-year to $3.0 million; the TTM value through Dec 2023 reached $3.0 million, changed N/A, while the annual FY2023 figure was $3.0 million, N/A changed from the prior year.
  • Convertible Debt for Q4 2023 was $3.0 million at Serina Therapeutics.
  • Across five years, Convertible Debt topped out at $3.0 million in Q4 2023 and bottomed at $3.0 million in Q4 2023.